1. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002.
2. Abdala N, Carney JM, Durante AJ, Klimov N, Ostrovski D, Somlai AM, Kozlov A, Heimer R: Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int J STD AIDS 2003, 14:697-703.
3. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE: Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995, 74:212-220.
4. Lincoln D, Petoumenos K, Dore GJ: HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003, 4:241-249.
5. Solomon SS, SriKrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, Anand S, Kumar MS, Latkin C, Solomon S, Celentano DD: High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008, 49:327-332.
6. Quan VM, Go VF, Nam LV, Bergenstrom A, Thuoc NP, Zenilman J, Latkin C, Celentano DD: Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care 2009, 21:7-16.
7. Tan Y, Wei QH, Chen LJ, Chan PC, Lai WS, He ML, Kung HF, Lee SS: Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS ONE 2008, 3: e3608.
8. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, Yu XF: Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004, 33:182-188.
9. McGovern BH, Wurcel A, Kim AY, Schulze zur WJ, Bica I, Zaman MT, Timm J, Walker BD, Lauer GM: Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006, 42:1663-1670.
10. Holsen DS, Harthug S, Myrmel H: Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis 1993, 12:673-676.
11. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003, 7:179-194.
12. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, Johnson AM, Dusheiko GM: Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007, 21:983-991.
13. Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich DT, Mullen MP, Thung SN, Fiel MI, Branch AD: Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008, 198:683-686.
14. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM,
Danta M: Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136:1609-1617.
15. Gerberding JL: Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. J Infect Dis 1994, 170:1410-1417.
16. Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS: Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940- 1990. Am J Epidemiol 2007.
17. Ticehurst JR, Hamzeh FM, Thomas DL: Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007, 45:2426-2433.
18. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
19. Drucker E, Alcabes PG, Marx PA: The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001, 358:1989-1992.
20. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A: The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009, 6:e1000198.
21. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-891.
22. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D: Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18(Suppl 1):S11-S19.
23. Quinn TC, Groseclose SL, Spence M, Provost V, Hook EW III: Evolution of the human immunodeficiency virus epidemic among patients attending sexually transmitted disease clinics: a decade of experience. J Infect Dis 1992, 165:541-544.
24. Kelen GD, Green GB, Purcell RH, Chan DW, Qaqish BF, Sivertson KT, Quinn TC: Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992, 326:1399-1404.
25. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
26. Thomas DL, Astemborski J, Vlahov D, Strathdee SA, Ray SC, Nelson KE, Galai N, Nolt KR, Laeyendecker O, Todd JA: Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000, 181:844-851.
27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
28. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
29. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ: Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
30. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A: End-stage liver disease in persons with hemophilia and transfusion- associated infections. Blood 2002, 100:1584-1589.
31. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE, AIDS Clinical Trials Groups 383 Study Team: Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002, 16:1915-1923.
32. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
33. Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
34. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR: Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection. Clin Infect Dis 2001, 32:492-497.
35. Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L: Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics 2008, 49:494-501.
36. Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP: Self- reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007, 8:320-327.
37. Mahoney FJ, Stewart K, Hu HX, Coleman P, Alter MJ: Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997, 157:2601-2605.
38. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V, Tural C: Europeans AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
39. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49(4):1335-1374.
40. Centers for Disease Control and Prevention: Guidelines for Preventing Opportunistic Infections in HIV-Infected Adults and Adolescents Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009, 58:1-206.
41. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM: Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007, 22:1510-1518.
42. Lee SR, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Friel T, Berne CA, Kardos KW: Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010, 48:15-17.
43. Soriano V, Maida I, Nunez M, Garcia-Samaniego J, Barreiro P, Martin- Carbonero L, Gonzalez-Lahoz J: Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon- based therapies. Antivir Ther 2004, 9:987-992.
44. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von- Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellon JM, Gonzalez- Garcia J: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50:407-413.
45. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
46. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL: Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997, 35:3274-7.